These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 14666894)

  • 1. New test predicts heart risk.
    FDA Consum; 2003; 37(5):6. PubMed ID: 14666894
    [No Abstract]   [Full Text] [Related]  

  • 2. Two markers complement each other in identifying risk.
    SoRelle R
    Circulation; 2004 Feb; 109(7):e9012. PubMed ID: 14981022
    [No Abstract]   [Full Text] [Related]  

  • 3. Lp-PLA2: an emerging biomarker of coronary heart disease.
    Dada N; Kim NW; Wolfert RL
    Expert Rev Mol Diagn; 2002 Jan; 2(1):17-22. PubMed ID: 11963798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PLAC test for identification of individuals at increased risk for coronary heart disease.
    Hoogeveen RC; Ballantyne CM
    Expert Rev Mol Diagn; 2005 Jan; 5(1):9-14. PubMed ID: 15723587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting cardiovascular risk: so what do we do now?
    Lloyd-Jones DM; Tian L
    Arch Intern Med; 2006 Jul; 166(13):1342-4. PubMed ID: 16831997
    [No Abstract]   [Full Text] [Related]  

  • 6. Improved identification of patients with coronary artery disease by the use of new lipid and lipoprotein biomarkers.
    Johnston N; Jernberg T; Lagerqvist B; Siegbahn A; Wallentin L
    Am J Cardiol; 2006 Mar; 97(5):640-5. PubMed ID: 16490429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA approves test for heart-disease marker.
    Health News; 2003 Oct; 9(10):10. PubMed ID: 14619771
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of low-density lipoprotein apheresis on lipoprotein-associated phospholipase A2.
    Moriarty PM; Gibson CA
    Am J Cardiol; 2005 May; 95(10):1246-7. PubMed ID: 15878003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stopping stroke before it strikes.
    Bloom S
    J Clin Invest; 2005 Aug; 115(8):1968. PubMed ID: 16075036
    [No Abstract]   [Full Text] [Related]  

  • 10. New tests for heart disease: promise but no payoff. Three new blood tests designed to detect early heart disease aren't quite ready for prime time.
    Harv Heart Lett; 2005 Jul; 15(11):6--7. PubMed ID: 16149177
    [No Abstract]   [Full Text] [Related]  

  • 11. Inflammatory markers of coronary risk.
    Rader DJ
    N Engl J Med; 2000 Oct; 343(16):1179-82. PubMed ID: 11036126
    [No Abstract]   [Full Text] [Related]  

  • 12. Lipoprotein-associated phospholipase A2 and cardiovascular risk: state of the evidence and future directions.
    Iribarren C
    Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):5-6. PubMed ID: 16373620
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum paraoxonase and platelet-activating factor acetylhydrolase in chronic renal failure.
    Hasselwander O; McMaster D; Fogarty DG; Maxwell AP; Nicholls DP; Young IS
    Clin Chem; 1998 Jan; 44(1):179-81. PubMed ID: 9550577
    [No Abstract]   [Full Text] [Related]  

  • 14. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
    Ballantyne CM; Hoogeveen RC; Bang H; Coresh J; Folsom AR; Heiss G; Sharrett AR
    Circulation; 2004 Feb; 109(7):837-42. PubMed ID: 14757686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When is a new prediction marker useful? A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk.
    Greenland P; O'Malley PG
    Arch Intern Med; 2005 Nov; 165(21):2454-6. PubMed ID: 16314539
    [No Abstract]   [Full Text] [Related]  

  • 16. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress.
    Koenig W; Twardella D; Brenner H; Rothenbacher D
    Arterioscler Thromb Vasc Biol; 2006 Jul; 26(7):1586-93. PubMed ID: 16627803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.
    Packard CJ; O'Reilly DS; Caslake MJ; McMahon AD; Ford I; Cooney J; Macphee CH; Suckling KE; Krishna M; Wilkinson FE; Rumley A; Lowe GD
    N Engl J Med; 2000 Oct; 343(16):1148-55. PubMed ID: 11036120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lp-PLA2 activity and PLA2G7 A379V genotype in patients with diabetes mellitus.
    Wootton PT; Stephens JW; Hurel SJ; Durand H; Cooper J; Ninio E; Humphries SE; Talmud PJ
    Atherosclerosis; 2006 Nov; 189(1):149-56. PubMed ID: 16438975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lp-PLA2: a new marker of vascular risk.
    Med Lett Drugs Ther; 2003 Oct; 45(1167):83. PubMed ID: 14534508
    [No Abstract]   [Full Text] [Related]  

  • 20. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany.
    Koenig W; Khuseyinova N; Löwel H; Trischler G; Meisinger C
    Circulation; 2004 Oct; 110(14):1903-8. PubMed ID: 15451783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.